For example, in the phase 1b study of triple-combination therapies (encorafenib and cetuximab with alpelisib) in colorectal cancer (BRAF-mutant), the incidence of hyperglycemia was 39.3% (16), while a phase II study of alpelisib plus fulvestrant in hormone receptor-positive breast cancer resulted in 29% of hyperglycemia (35). This evidence concerns the gene BRAF and colorectal cancer.